Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Zymeworks Inc ZYME

Healthcare Biotechnology
Zymeworks Inc. is a global biotechnology company. The Company is engaged in the discovery, development, and commercialization of multifunctional biotherapeutics to treat cancer and other serious diseases. Its complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop differentiated antibody-based... see more

Recent & Breaking News (NDAQ:ZYME)

Zymeworks' Lead Asset, ZW25, Granted Fast Track Designation from the FDA

Business Wire May 29, 2019

Zymeworks Earns Milestone Payment in Merck Collaboration

Business Wire May 29, 2019

Zymeworks to Present at Jefferies 2019 Global Healthcare Conference

Business Wire May 28, 2019

Zymeworks Announces Corporate Update Conference Call

Business Wire May 23, 2019

Zymeworks Enters its First ZymeLink(TM) Antibody-Drug Conjugate Platform Licensing Agreement with Iconic Therapeutics

Business Wire May 14, 2019

Zymeworks Announces Election of Directors and Voting Results from Shareholder Meeting

Business Wire May 3, 2019

Zymeworks Reports 2019 First Quarter Financial Results

Business Wire May 2, 2019

Zymeworks Adds Experienced Executives to Management Team to Support Expanding Clinical Development

Business Wire April 30, 2019

Zymeworks Adds Experienced Executives to Management Team to Support Expanding Clinical Development

Press Releases April 30, 2019

Daiichi Sankyo Selects Lead Candidate Built on Zymeworks' Azymetric(TM) Bispecific Platform

Business Wire April 25, 2019

Daiichi Sankyo Selects Lead Candidate Built on Zymeworks' Azymetric(TM) Bispecific Platform

Press Releases April 25, 2019

Zymeworks to Present at Bloom Burton & Co. Healthcare Investor Conference 2019

Press Releases April 23, 2019

Zymeworks Opens Phase 2 Clinical Trial for ZW25 in First-Line HER2-Expressing Metastatic Gastroesophageal Cancers

Business Wire April 15, 2019

Positive Results and New Technology Give Rise to Antibody Dominance

GlobeNewswire March 27, 2019

Zymeworks Reports 2018 Year-End Financial Results

Business Wire March 6, 2019

Zymeworks to Present at Barclays 2019 Global Healthcare Conference

Business Wire March 5, 2019

Zymeworks Reports Second Investigational New Drug (IND)-Submission Milestone Achieved in Lilly Collaboration

Business Wire January 17, 2019

Zymeworks Highlights 2018 Achievements and Announces 2019 Priorities

Business Wire January 6, 2019

Zymeworks Submits Investigational New Drug (IND) Application for ZW49 and Presents IND-Enabling Studies at the San Antonio Breast Cancer Symposium

Business Wire December 8, 2018

Zymeworks and BeiGene Announce License and Collaboration Agreement for Zymeworks’ HER2-Targeted Therapeutic Candidates, ZW25 and ZW49, in Asia-Pacific and Research and License Agreement for Zymeworks’ Azymetric™ and EFECT™ Platforms Globally

Business Wire November 27, 2018